ArticleEuropean thyroid journal2020
Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.
Article in European thyroid journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease.European thyroid journal · 2024Pooled it
- Thyroid disease-specific quality of life questionnaires - A systematic review.Endocrinology, diabetes & metabolism · 2022Pooled it
- Current insights of applying MRI in Graves' ophthalmopathy.Frontiers in endocrinology · 2022Pooled it
- Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study.Endocrine · 2024Trial
- Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease.Acta ophthalmologica · 2026Article
- Effectiveness of intravenous glucocorticoids in active thyroid eye disease patients with low clinical activity scores.Endocrine · 2025Article
- Article
- Apparent diffusion coefficient: a predictor of the efficacy of glucocorticoid therapy in active moderate-severe thyroid eye disease: a retrospective cohort study.BMC endocrine disorders · 2025Article
- Long-term outcome of Graves' orbitopathy following treatment with sirolimus.Journal of endocrinological investigation · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- Application progress of magnetic resonance imaging in thyroid associated ophthalmopathy.Frontiers in endocrinology · 2025Review
- Review
- The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (London, England) · 2024Review
- Quantitative assessment of extraocular muscles in Graves' ophthalmopathy using T1 mapping.European radiology · 2023Article
- Facial expression of patients with Graves' orbitopathy.Journal of endocrinological investigation · 2023Article
- Teprotumumab in thyroid eye disease: wonder drug or great divider?European thyroid journal · 2023Article
- Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.Thyroid : official journal of the American Thyroid Association · 2022Article
- Rituximab in the treatment of Graves' orbitopathy: latest updates and perspectives.Endocrine connections · 2022Review
- Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association.European thyroid journal · 2022Article
- Sirolimus as a second-line treatment for Graves' orbitopathy.Journal of endocrinological investigation · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Standardization of treatment outcomes in randomized clinical trials (RCTs) for active, moderate-to-severe Graves' orbitopathy (GO) is needed to make results of different RCTs comparable and to draw sound conclusions on the efficacy of a given treatment. Both subjective patient-reported outcome (PRO) and objective clinician-reported outcome (CRO) are important in this regard. In this paper, it is proposed that primary PRO should be the evaluation of treatment-related changes in the quality of life by the use of a validated and disease-specific questionnaire (GO-QoL). The proposed primary CRO is a revised composite index, which includes only objective items and provides an overall assessment of the effects of treatment. Secondary outcomes should also be provided in RCTs to show the effects of treatment on individual features of GO, as well on persistence of activity (by the 7-item Clinical Activity Score), safety, relapses of GO, need for subsequent medical and/or surgical treatments, and other indicators (orbital volume, cytokines, TSH receptor antibody levels). Assessment of the overall response to treatment by primary and secondary outcomes should be made 3 months after treatment completion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.